Yahoo Finance

Apricus Biosciences submits response for Vitaros market application

Apricus Biosciences announced that the company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application ...
NBC News

Apricus Biosciences Will Request Approval of Vitaros(R) as a Treatment for Erectile Dysfunction in Switzerland, Based on Guidance From Swiss Regulatory Authorities

SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...
NBC News

Apricus Biosciences Requests Approval of Vitaros(R) as a Treatment for Erectile Dysfunction in Europe

SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...
Yahoo Finance

Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA

SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of ...
Nasdaq

Apricus' Vitaros Approved in Europe - Analyst Blog

Apricus Biosciences, Inc. ( APRI) recently announced that its erectile dysfunction (ED) drug, Vitaros, has been approved under the European Decentralized Procedure (DCP). Apricus, along with its ...